Pr Eric Raymond is a Professor of Medical Oncology and Chair of Medical Oncology at the Centre Universitaire Hospitalier Vaudois (CHUV) & University of Lausanne (UNIL), Switzerland. His research has focused on molecular pharmacology, translational research, and early clinical trials (phase 0, I and early phase II). Some of his team’s previous works were seminal in the development and registration of oxaliplatin, sunitinib, temsirolimus, and everolimus. More recently his team has focused on development of novel anticancer drugs that interact with epigenetic factors, tumour microenvironment, including antiangiogenic agents and drugs affecting tumour metabolism, as well as tumour biomarkers for precision medicine in a variety of tumours including head & neck carcinomas, neuroendocrine tumours, pancreatic adenocarcinomas, brain tumours, and hepatocarcinomas. Pr Raymond has published papers in top tier journals such as the New England Journal of Medicine, Lancet, Nature Reviews Drug Discovery and the Journal of Clinical Oncology. He is a former Editorial Board Member of Journal of Clinical Oncology and is currently an Editorial Board Member of the journals Cancer Chemotherapy Pharmacology, Investigational New Drugs, and Targeted Oncology.